Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial With Docetaxel, Oxaliplatin and S1 as First-line Treatment for Patients With Non-resectable Adenocarcinoma of the Esophagus or Gastric

NCT01928524 is registered in ClinicalTrials.gov with Per Pfeiffer as lead sponsor.

NCT NCT01928524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01928524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial With Docetaxel, Oxaliplatin and S1 as First-line Treatment for Patients With Non-resectable Adenocarcinoma of the Esophagus or Gastric
Lead sponsor
Per Pfeiffer
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2013
Completion date
December 17, 2015
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

first-line treatment for patients with non-resectable gastric cancer or cancer of the esophagus or